Delivery Order SPE2DB22D2006-SPE2DB25FW2VL
- Not listed
- The Defense Logistics Agency awarded a $7,159.80 delivery order to AmerisourceBergen Drug Corp for the supply of Lyrica 100 mg capsules (90-count units) under a firm fixed-price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,786.46 on July 18, 2025, for the supply of Lyrica 50 mg capsules (90-count units). This contract was awarded on a firm fixed price basis with no set-aside designation, indicating competitive award conditions. The order is scheduled for completion by July 21, 2025, and is being funded through the Medical Supply Chain division of the Department of...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,524.66, is for the delivery of Lyrica 50 mg capsules. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of June 7, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
- The Defense Logistics Agency awarded a $1,445.82 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 unit-dose capsules of Lyrica (pregabalin) 75 mg, with an ultimate completion date of July 21, 2025. This is a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where the vendor maintains its corporate headquarters. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,166.99 firm fixed price delivery order is for the supply of Lyrica 75 mg capsules, a medication used for various conditions including neuropathic pain, fibromyalgia, and epilepsy. The contract has an ultimate completion date of November 20, 2024 and there is no set-aside designation, indicating open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,571.40 firm-fixed-price delivery order is for 4,566,790,170 Lyrica 100 mg capsules in quantities of 90 per bottle. The contract has an ultimate completion date of December 24, 2024 and was awarded on December 23, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,463.68 contract is for the delivery of Lyrica 300 mg capsules, a neurological treatment medication. The award has an ultimate completion date of July 17, 2025 and is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,281.97 firm fixed-price delivery order contract covers the supply of LYRICA 100 mg capsules, a prescription medication primarily used to treat neuropathic pain. The contract has an ultimate completion date of March 28, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This federal contract award, valued at $2,905.99, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order for the supply of Lyrica 300 mg capsules, a medication used for the treatment of neuropathic pain, nerve pain, and fibromyalgia. The contract has an ultimate completion date of December 30, 2024 and is a Firm Fixed Price arrangement. This award is part of a larger Indefinite Delivery Contract...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,445.82 firm-fixed-price delivery order is for the supply of Lyrica 75 mg capsules, a medication used to treat certain types of nerve pain. The contract has a completion date of February 19, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW2VLDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,100.28 for Lyrica 300 mg capsules (90-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. No set-aside designation was utilized for this award. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply agreement supporting military healthcare programs and federal medical procurement needs. Lyrica (pregabalin) is a neurological medication commonly used in military and veteran healthcare systems for pain management and neuropathic conditions. The award reflects the company's ongoing role as a critical pharmaceutical distributor for the Defense Health Agency and other federal healthcare entities, leveraging its position as a prime vendor under the DLA's global pharmaceutical support framework, which encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 7/25/25 |